CA-G2-RISK-SOLUTIONS
27.8.2024 15:08:33 CEST | Business Wire | Press release
G2 Risk Solutions (G2RS), the global leader in risk and compliance business intelligence, today celebrates the release of the API version of its cornerstone product, advancing its vision to simplify and optimize merchant risk management for acquiring banks and payments facilitators. Global Onboarding, an AI-powered merchant onboarding solution, helps users safely onboard new merchants quickly with highly accurate predictive risk assessments.
One solution to manage it all
Global Onboarding is the final building block in a unified solution that integrates onboarding seamlessly with G2RS monitoring products, Persistent Merchant Monitoring and Transaction Laundering Detection. For the first time, risk managers have the ability within a single platform to underwrite merchants, approve them intelligently at scale, and then usher the flow of approved merchants in and out of activities that continuously monitor for a wide variety of illegal and/or violative conduct.
“We’re thrilled to be the first to deliver an integrated solution based on our Merchant Map® and enhanced AI,” said Brian Longe, G2RS chief executive officer. “Our customers need to operate quickly and accurately to capture new merchant opportunities while also minimizing merchant portfolio risk. Speed is money, and our solution finally lets them scale up in a safe, smart way.”
Innovation to match evolution
As the e-commerce landscape expands with new online merchants and digital payment options, competition has increased. At the same time, regulations have gotten increasingly complex and punitive, and bad actors have become more sophisticated. Companies need innovation and agility to stay ahead in this ecosystem. Effective merchant onboarding is a critical step in the efficient setup of merchant clients for secure digital payment acceptance while avoiding exposure to fraud, card service rule infractions, and regulatory fines.
"The expanding e-commerce landscape presents exciting opportunities and significant challenges for the payments industry," said Rochelle Blease, G2RS president of merchant risk solutions. "Global Onboarding empowers financial institutions and other payments providers to navigate this dynamic environment confidently, acting swiftly on new business opportunities while minimizing exposure to illegal activity and non-compliance."
Combining the industry’s best resources
Global Onboarding incorporates advanced proprietary technology to enable rapid, confident merchant onboarding. The solution includes robust G2RS risk mitigation and business enablement capabilities that are unique within the payments industry, including:
- Merchant Map®, a proprietary, industry-exclusive merchant behavior database built over 20+ years with billions of data points, all validated by G2RS expert analysts.
- Compass Score®, a comprehensive, AI-driven score that predicts the risk of problematic merchant activity during the next 12 months. The scoring models synthesize data from the Merchant Map and additional data sources, including watchlists and sanctions registries, consumer ratings and adverse media, and risk-based insights for content compliance and operational risk.
- Merchant lifecycle risk management, a comprehensive approach covering risk from underwriting and onboarding to ongoing monitoring and transaction laundering detection, with re-underwriting as needed for audits or investigations.
"Our global customers need tools that keep pace with the increasing complexity and growth of the industry,” said Gavin Andrews, G2RS director of product management. “The AI-powered insights, comprehensive risk evaluations, and automation-ready workflows in Global Onboarding address the critical needs for efficiency, accuracy, and smarter decision-making when onboarding merchants. This is fintech that helps payments providers more confidently scale their operations.”
To learn more, visit g2risksolutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827954388/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom